← Back
$DNTH All transactions

Dianthus Therapeutics, Inc. /DE/

▼ SELL 10b5-1 Plan

$ Value

$5.0M

Shares

59,800

Price

$84

Filed

Apr 1

Insider

Name

Savitz Ryan

Title

EVP, CFO & CBO

CIK

0001992324

Roles

Officer

Transaction Details

Transaction Date

2026-03-31

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

26,701

Footnotes

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.74 to $78.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.74 to $79.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.11 to $81.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.15 to $81.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.25 to $84.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.25 to $85.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.25 to $85.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. | The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. | The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Filing Info

Accession No.

0001992324-26-000004

Form Type

4

Issuer CIK

0001690585

Savitz Ryan's History

Date Ticker Type Value
2026-04-09 DNTH M $147K
2026-04-09 DNTH $739K
2026-04-09 DNTH M $0
2026-03-31 DNTH M $628K
2026-03-31 DNTH M $715K
2026-03-31 DNTH $109K
2026-03-31 DNTH $1.7M
2026-03-31 DNTH $119K
2026-03-31 DNTH $65K
2026-03-31 DNTH $196K

Other Insiders at DNTH (90d)

Insider Bought Sold Last
CARR EDWARD
CHIEF ACCOUNTING OFFICER
2026-02-03
Garcia Marino
CEO AND PRESIDENT
2026-02-03
Soteropoulos Paula $2.2M 2026-03-31
Veness Adam M
SVP, General Counsel and Sec.
2026-02-03
Randhawa Simrat
EVP, Head of R&D
2026-02-03
Savitz Ryan
EVP, CFO & CBO
$5.2M 2026-04-09